BFRI
Biofrontera Inc.
BFRI lost money over the past year, so it has no meaningful PE right now. Analysts expect earnings to recover and profitability to improve.
BFRI Fundamentals
| Metric | Status |
|---|---|
| Strong | |
| Under pressure | |
| Under pressure | |
| Unavailable |
BFRI's revenue is currently strong, but its profitability and cash flow are under pressure. There isn't enough data to rate its balance sheet.
BFRI PE Valuation
BFRI has no meaningful PE right now: it lost money over the past year. If it returns to profit as analysts expect, today's price would be 3.7x next year's earnings.
BFRI Forward outlook
| Metric | Outlook |
|---|---|
| -- | |
| Returning to profit | |
| Growth | |
| Strongly improving | |
| Limited | |
| High |
Analysts expect BFRI to return to profit, with revenue growing.
BFRI Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Forward | $0.25 | — |
| Q3 2024 | -$1.33 | +$18.59 |
| Q2 2024 | -$4.99 | +$12.40 |
| Q1 2024 | -$12.17 | -$1.06 |
| Q4 2023 | -$14.89 | -2541% |
BFRI is still losing money, but far less than before: $0.46 per share over the past year, against $56.97 at its worst in late 2021.
BFRI Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q2 2026 | $12M | +33% |
| Q1 2026 | $10.1M | +17% |
| Q4 2025 | $17.1M | +36% |
| Q3 2025 | $7M | -22% |
| Q2 2025 | $9M | +15% |
| Q1 2025 | $8.6M | +8.5% |
| Q4 2024 | $12.6M | +19% |
| Q3 2024 | $9M | +1.3% |
BFRI's revenue is growing: $12M last quarter, up 33% from the same quarter a year ago.
| Quarter | Margin | YoY |
|---|---|---|
| Q2 2026 | -4.4% | +52 points |
| Q1 2026 | -43% | +10 points |
| Q4 2025 | 27% | +40 points |
| Q3 2025 | -90% | -35 points |
| Q2 2025 | -56% | +8.4 points |
| Q1 2025 | -53% | +16 points |
| Q4 2024 | -14% | +23 points |
| Q3 2024 | -55% | -3.1 points |
BFRI's operating margin was −4.4% last quarter, up 52 points from the same quarter a year ago.
BFRI Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q2 2026 | -$1.7M | +$1.4M |
| Q1 2026 | -$75K | +$4M |
| Q4 2025 | -$2.4M | -$1.4M |
| Q3 2025 | -$3.8M | -$2.6M |
| Q2 2025 | -$3M | +$1.6M |
| Q1 2025 | -$4.1M | -$738K |
| Q4 2024 | -$1M | +$7.8M |
| Q3 2024 | -$1.2M | +$796K |
BFRI has burned cash in almost every quarter: −$8M over the past year, against −$9M the year before.
BFRI Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | +11% | +1.2M shares |
| 1 year | +38% | +3.6M shares |
| 3 years | +868% | +11.6M shares |
| 5 years | +2128% | +12.3M shares |
BFRI has 13M diluted shares, up 38% from a year ago.
| Quarter | Spent |
|---|---|
| Q2 2021 | — |
| Q1 2021 | — |
| Q4 2020 | — |
| Q3 2020 | — |
| Q2 2020 | — |
| Q1 2020 | — |
BFRI Net Leverage
BFRI's operating earnings (EBITDA) were negative over the past year, so its debt can't be measured against them.
BFRI Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 44.2 | Neutral |
| Stochastic | 10.9 | Oversold |
BFRI's weekly RSI is 44 (neutral) and its Stochastic is 11 (oversold).
BFRI PE vs Healthcare Sector
BFRI has no meaningful PE right now: it lost money over the past year.
BFRI Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $0.92 | 1.1% above |
| 20 week MA | $1.15 | 19% below |
| 50 week MA | $1.00 | 7% below |
| 100 week MA | $0.95 | 2.1% below |
| 200 week MA | $3.17 | 71% below |
BFRI has bounced recently, but its long-term trend is still down: it's above its 8-week average, but 71% below its 200-week average.
BFRI Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2021 | $88.2 | $263.4 | +198% |
| 2022 | $263.4 | $18.6 | -93% |
| 2023 | $18.6 | $2.77 | -85% |
| 2024 | $2.77 | $1.11 | -60% |
| 2025 | $1.11 | $0.72 | -35% |
| 2026 YTD | $0.72 | $0.93 | +29% |
BFRI has finished four years in a row lower, and it's up 29% so far in 2026.